6ZE1 image
Deposition Date 2020-06-15
Release Date 2021-06-30
Last Version Date 2024-11-13
Entry Detail
PDB ID:
6ZE1
Keywords:
Title:
human NBD1 of CFTR in complex with nanobody G11a
Biological Source:
Source Organism:
Homo sapiens (Taxon ID: 9606)
Lama glama (Taxon ID: 9844)
Host Organism:
Method Details:
Experimental Method:
Resolution:
2.71 Å
R-Value Free:
0.25
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 61 2 2
Macromolecular Entities
Polymer Type:polypeptide(L)
Molecule:Cystic fibrosis transmembrane conductance regulator
Chain IDs:A
Chain Length:261
Number of Molecules:1
Biological Source:Homo sapiens
Polymer Type:polypeptide(L)
Molecule:G11a nanobody
Chain IDs:B
Chain Length:147
Number of Molecules:1
Biological Source:Lama glama
Primary Citation
A topological switch in CFTR modulates channel activity and sensitivity to unfolding.
Nat.Chem.Biol. 17 989 997 (2021)
PMID: 34341587 DOI: 10.1038/s41589-021-00844-0

Abstact

The cystic fibrosis transmembrane conductance regulator (CFTR) anion channel is essential to maintain fluid homeostasis in key organs. Functional impairment of CFTR due to mutations in the cftr gene leads to cystic fibrosis. Here, we show that the first nucleotide-binding domain (NBD1) of CFTR can spontaneously adopt an alternate conformation that departs from the canonical NBD fold previously observed. Crystallography reveals that this conformation involves a topological reorganization of NBD1. Single-molecule fluorescence resonance energy transfer microscopy shows that the equilibrium between the conformations is regulated by adenosine triphosphate binding. However, under destabilizing conditions, such as the disease-causing mutation F508del, this conformational flexibility enables unfolding of the β-subdomain. Our data indicate that, in wild-type CFTR, this conformational transition of NBD1 regulates channel function, but, in the presence of the F508del mutation, it allows domain misfolding and subsequent protein degradation. Our work provides a framework to design conformation-specific therapeutics to prevent noxious transitions.

Legend

Protein

Chemical

Disease

Primary Citation of related structures